ALGN:NGS-Align Technology Inc. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 280.32

Change

+2.24 (+0.81)%

Market Cap

USD 7.53B

Volume

0.52M

Analyst Target

USD 325.93
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Align Technology Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage. Its segments are Clear Aligner and Scanners & Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.44 (-0.61%)

USD 29.04B
PODD Insulet Corporation

-1.79 (-0.77%)

USD 16.66B
BRKR Bruker Corporation

+0.46 (+0.79%)

USD 9.04B
MASI Masimo Corporation

+1.84 (+1.30%)

USD 7.53B
TMDX TransMedics Group Inc

-6.58 (-7.44%)

USD 4.17B
AXNX Axonics Modulation Technologie..

+0.05 (+0.07%)

USD 3.59B
PRCT Procept Biorobotics Corp

-3.66 (-3.79%)

USD 3.50B
LIVN LivaNova PLC

-1.63 (-3.08%)

USD 2.90B
QDEL Quidel Corporation

+0.62 (+1.62%)

USD 2.67B
NARI Inari Medical Inc

-2.08 (-4.23%)

USD 2.57B

ETFs Containing ALGN

UGCE 3.86 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

-0.01 (-0.09%)

USD 2.57B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

-1.75 (-0.09%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.31% 70% C- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.31% 70% C- 56% F
Trailing 12 Months  
Capital Gain -3.79% 70% C- 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.79% 70% C- 42% F
Trailing 5 Years  
Capital Gain -13.11% 75% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.11% 75% C 39% F
Average Annual (5 Year Horizon)  
Capital Gain 26.93% 73% C 83% B
Dividend Return 26.93% 73% C 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 72.48% 41% F 22% F
Risk Adjusted Return 37.15% 86% B+ 71% C-
Market Capitalization 7.53B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.90 40% 22%
Price/Book Ratio 6.53 25% 17%
Price / Cash Flow Ratio 26.64 12% 10%
Price/Free Cash Flow Ratio 28.60 9% 8%
Management Effectiveness  
Return on Equity 12.77% 91% 82%
Return on Invested Capital 12.37% 86% 82%
Return on Assets 7.02% 95% 91%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector